Mr David Rosenthal > Dechert LLP > New York, United States > Lawyer Profile
Dechert LLP Offices
![Dechert LLP company logo](https://www.legal500.com/wp-content/uploads/sites/13/2022/05/9038.jpg?v=1653297619)
Three Bryant Park, 1095 Avenue of the Americas
NEW YORK, NY 10036-6797
NEW YORK
United States
- Firm Profile
- Go to...
Mr David Rosenthal
![David Rosenthal photo](https://www.legal500.com/wp-content/uploads/sites/13/2021/06/david-rosenthal-portrait-240x300.jpg)
Work Department
Corporate
Position
Partner
Career
David S. Rosenthal, co-chair of Dechert’s Global Corporate Finance and Capital Markets Practice and co-lead of the firm’s Life Sciences Practice, represents publicly and privately held corporations, investment banks, and venture capital firms focused on the life sciences and medical device, technology, media, and other growth sectors. He represents clients in corporate finance transactions, mergers and acquisitions, joint ventures, licensings and strategic alliances.
Mr. Rosenthal regularly advises issuers and investment banks in public and private offerings of equity and debt, including IPOs, secondary offerings, confidentially marketed public offerings (CMPOs), at-the-market (ATM) financings, registered direct offerings, and PIPEs, as well as seed financings and later-stage venture capital financings. He also has particular experience counseling foreign private issuers in migrating to and listing on the U.S. stock exchanges. Mr. Rosenthal also counsels clients in general corporate matters, Securities and Exchange Commission (SEC) compliance, and corporate governance, and often acts as outside general corporate and securities counsel to both emerging and publicly traded companies. These activities have included business and corporate planning and structuring as well as other contract negotiations, and contractual and other commercial dealings.
In the mergers and acquisitions area, Mr. Rosenthal has represented buyers and sellers in leveraged and unleveraged mergers, acquisitions, and private equity transactions as well as divestitures and dispositions of business and subsidiaries. The American Lawyer selected Mr. Rosenthal as Dealmaker of the Week for his skillful representation of Inhibitex in its sale to Bristol-Myers Squibb for US$2.5 billion, which represented a 163 percent premium to the closing price of the company’s stock the day before the transaction signed, and is believed to be one of the largest premiums in deal history.
Education
- Wesleyan University, B.A., cum laude
- Boston University School of Law, J.D., cum laude
Top Tier Firm Rankings
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Environment > Environment: transactional
- Antitrust > Civil litigation/class actions: defense
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Real estate > Real estate finance
- Finance > Structured finance: securitization
Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Dispute resolution > Securities litigation: defense
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > E-discovery
- Finance > Fintech
- Dispute resolution > General commercial disputes
- Dispute resolution > International litigation
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Antitrust > Merger control
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Finance > Restructuring (including bankruptcy): corporate
- Tax > US taxes: non-contentious
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- International trade > Customs, export controls and economic sanctions
- Dispute resolution > International arbitration
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Investment fund formation and management > Private equity funds (including venture capital)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Intellectual property > Patents: litigation (full coverage)
- Finance > Capital markets: high-yield debt offerings
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Investment fund formation and management > Alternative/hedge funds
- Dispute resolution > Financial services litigation
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)